2023
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsFemaleHIV InfectionsHumansMassachusettsParturitionPregnancyProspective StudiesViral LoadConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-Engagement
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIV
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART doses
2015
Correlates and Experiences of HIV Stigma in Prisoners Living With HIV in Indonesia: A Mixed-Method Analysis
Culbert GJ, Earnshaw VA, Wulanyani NM, Wegman MP, Waluyo A, Altice FL. Correlates and Experiences of HIV Stigma in Prisoners Living With HIV in Indonesia: A Mixed-Method Analysis. Journal Of The Association Of Nurses In AIDS Care 2015, 26: 743-757. PMID: 26304049, PMCID: PMC4600662, DOI: 10.1016/j.jana.2015.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveHIV InfectionsHumansIndonesiaInterviews as TopicMaleMiddle AgedPrincipal Component AnalysisPrisonersPrisonsPsychiatric Status Rating ScalesQualitative ResearchSelf DisclosureSexual PartnersSocial DiscriminationSocial StigmaSurveys and QuestionnairesTruth DisclosureConceptsHIV stigmaExperiences of stigmaDrug-related offensesMixed-methods analysisDepth interviewsSyndemic natureLargest prisonFamily membersPrisonersHIV statusIndonesiaDrug useStigmaIncarcerationCurrent incarcerationGroup of HIVMale HIVStigma SurveyHIV treatmentExperienceHIVPrisonOffensesPrevention goalsStigma levels
2014
Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment
Krishnan A, Ferro EG, Weikum D, Vagenas P, Lama JR, Sanchez J, Altice FL. Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment. AIDS Care 2014, 27: 273-282. PMID: 25285464, PMCID: PMC4305474, DOI: 10.1080/09540121.2014.963014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcohol DrinkingAnti-Retroviral AgentsCell PhoneEducationFemaleHealth SurveysHIV InfectionsHomosexuality, MaleHumansMaleMedication AdherenceMiddle AgedPeruPovertyPrevalenceRisk FactorsSexual BehaviorSurveys and QuestionnairesTelemedicineText MessagingTransgender PersonsConceptsAlcohol use disorderTransgender womenMHealth acceptancePoor HIV treatment outcomesHIV treatment outcomesAntiretroviral therapy adherenceSuboptimal ART adherenceHIV risk behaviorsART adherenceRisky sexual behaviorPeruvian MSMTherapy adherenceHIV epidemicHIV preventionTreatment outcomesHIV interventionsUse disordersMedication remindersHealth professionalsHIVMSMConvenience sampleMost participantsIntervention strategiesStandardized assessmentOptimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimensGender disparities in HIV treatment outcomes following release from jail: results from a multicenter study.
Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. American Journal Of Public Health 2014, 104: 434-41. PMID: 24432878, PMCID: PMC3953795, DOI: 10.2105/ajph.2013.301553.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesTreatment outcomesViral suppressionJail detaineesMultisite prospective cohort studyOptimal antiretroviral therapy (ART) adherenceOptimal HIV treatment outcomesWorse HIV treatment outcomesMultiple logistic regression modelAntiretroviral therapy prescriptionHIV primary careHIV clinical careProspective cohort studyAntiretroviral therapy adherenceNon-Hispanic whitesLogistic regression modelsGreater comorbidityCohort studyEvaluable participantsMulticenter studyTherapy adherencePrimary careTherapy prescriptionClinical careHeroin use
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexoneHigh rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes. Drug And Alcohol Dependence 2013, 133: 154-160. PMID: 23769160, PMCID: PMC3786010, DOI: 10.1016/j.drugalcdep.2013.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsFemaleHIV InfectionsHumansMaleMedication AdherenceOpiate Substitution TreatmentPoliceRisk FactorsSubstance Abuse, IntravenousUkraineConceptsOpioid substitution therapyAntiretroviral therapyHIV transmissionHIV epidemicHigh-risk injection practicesSignificant independent correlatesMedication interruptionOST treatmentART prescriptionAdverse eventsSubstitution therapyIndependent correlatesWithdrawal symptomsMale genderEssential medicationsInjection practicesHealth outcomesLogistic regressionHIVPublic healthTherapyHigh rateHealthCorrelatesParticipantsContribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severityA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadoneAlcohol use disorders and antiretroviral therapy among prisoners in Argentina
Alpert M, Wickersham JA, Vázquez M, Altice FL. Alcohol use disorders and antiretroviral therapy among prisoners in Argentina. International Journal Of Prison Health 2013, 9: 40-50. PMID: 24772187, PMCID: PMC3999974, DOI: 10.1108/17449201311310797.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyUse disordersSecondary HIV preventionCent of subjectsCross-sectional surveyHIV careSubstance abuse patternsMajority of participantsIndependent correlatesHIV preventionTreatment outcomesGeneral populationHIVHealth care reformAbuse patternsAUDIT scaleCurrent incarcerationDisordersTherapyOne-thirdCare reformOne-quarterParticipantsFuture efforts
2012
Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients
Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, Shamai M, Amiri M, Nikaein S, Mansouri D, Masjedi M, Altice F. Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal Of STD & AIDS 2012, 23: e1-e4. PMID: 23033530, PMCID: PMC3495268, DOI: 10.1258/ijsa.2009.009093.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsFemaleHIV InfectionsHumansIranMaleMiddle AgedRisk FactorsTreatment OutcomeTuberculosisConceptsCombination antiretroviral therapyTreatment outcomesTB/HIV co-infected patientsHIV co-infected patientsCat II treatmentCo-infected patientsTB-HIV patientsSerum albumin levelIntravenous drug useRisk of deathLower body weightHistory of imprisonmentAntiretroviral therapyLaboratory characteristicsTB treatmentTuberculosis patientsAlbumin levelsHIV transmissionMean ageII treatmentTB centersAlcohol abuseBetter outcomesPatientsBody weight
2011
Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARVPRESERVING HUMAN RIGHTS IN THE ERA OF “TEST AND TREAT” FOR HIV PREVENTION
Fu JJ, Bazazi AR, Altice FL. PRESERVING HUMAN RIGHTS IN THE ERA OF “TEST AND TREAT” FOR HIV PREVENTION. American Journal Of Public Health 2011, 101: 198-199. PMID: 21228278, PMCID: PMC3020217, DOI: 10.2105/ajph.2010.300050.Peer-Reviewed Original ResearchAnti-Retroviral AgentsHealth BehaviorHealth Care RationingHIV InfectionsHuman RightsHumansSexual BehaviorMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research
Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25: 279-290. PMID: 21239892, DOI: 10.1097/qad.0b013e328340feb0.Peer-Reviewed Original ResearchConceptsClinical outcomesPrescribed therapyFuture clinical careSuboptimal persistenceVirological failureAntiretroviral resistanceMedication persistenceHIV infectionMedication treatmentHIV treatmentCertain regimensClinical consequencesClinical carePatient behaviorPatientsContinuous treatmentUnderrecognized aspectsTherapyAdherenceHIVTreatmentShort durationCurrent literatureDurationIntervention
2010
Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scale
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2007
Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsIntegration and co-location of HIV/AIDS, tuberculosis and drug treatment services
Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal Of Drug Policy 2007, 18: 306-312. PMID: 17689379, PMCID: PMC2696234, DOI: 10.1016/j.drugpo.2007.03.001.Peer-Reviewed Original ResearchConceptsInjection drug useSubstance use treatmentDrug usersEffective substance use treatmentTraining Community Health WorkersActive injection drug useUse treatmentIntegrated care delivery systemSpecialist care providersAdverse drug eventsCommunity health workersComplex patient populationInjection drug usersAdverse side effectsDrug treatment servicesDrug-drug interactionsDetection of tuberculosisCare delivery systemHIV/AIDSAntiretroviral medicationsMedication adherencePatient populationDrug eventsHIV epidemicHealth workers